TDP-43 in AD/ADRD: Establish biomarkers and dementia risk profiles (Milestone 9.T)
In Progress
Timeline Start - End
2020 - 2030Research Implementation Area
BiomarkersAD-Related Dementias Focus
Develop biomarkers, classifiers, and risk profiles to establish in-vivo diagnostic criteria for LATE in persons without cognitive symptoms and in persons with amnestic or other relevant late-life dementia syndromes, assuring diversity, inclusion and equity.
Success Criteria
- At least three new projects to develop biomarker profiles for clinical trials for TDP-43 proteinopathy in common dementias.
Summary of Key Accomplishments
Currently, biomarkers that reveal pathological changes in TDP-43, a protein linked to various types of dementia, are needed across all stages of disease. NIH supports multiple funding opportunities to develop biomarkers for TDP-43 neuropathology. Recently, researchers showed that detection of extremely low levels of TDP-43 may be overcome by technological advances to amplify TDP-43 from cerebral spinal fluid or isolate it from plasma. Additionally, NIH supports the National Centralized Repository for Alzheimer’s Disease and Related Dementias (NCRAD), which is a repository for biological specimens available to researchers to help identify disease genes and support biomarker development for AD/ADRDs, including for TDP-43.
The key accomplishments summary is current as of July 2022.
Accomplishments/Implementation Activities
Funding Initiatives
Research Programs and Resources
- Center without Walls for PET Ligand Development for Alzheimer's disease related dementias (ADRDs) (U19)
- National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)
Research Highlights
Relevant Recommendations
- 2019 ADRD Summit: Emerging Scientific Topics, Focus Area 1: TDP-43 Pathology in Common Dementias, Milestone 1
- 2022 ADRD Summit: MED Special Topic: LATE (TDP-43 in Common Late-Onset Dementias), Milestone 2, Priority 2